1. Home
  2. KGC vs UTHR Comparison

KGC vs UTHR Comparison

Compare KGC & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KGC
  • UTHR
  • Stock Information
  • Founded
  • KGC 1993
  • UTHR 1996
  • Country
  • KGC Canada
  • UTHR United States
  • Employees
  • KGC N/A
  • UTHR N/A
  • Industry
  • KGC Precious Metals
  • UTHR Biotechnology: Pharmaceutical Preparations
  • Sector
  • KGC Basic Materials
  • UTHR Health Care
  • Exchange
  • KGC Nasdaq
  • UTHR Nasdaq
  • Market Cap
  • KGC 15.8B
  • UTHR 14.4B
  • IPO Year
  • KGC N/A
  • UTHR 1999
  • Fundamental
  • Price
  • KGC $15.75
  • UTHR $323.32
  • Analyst Decision
  • KGC Buy
  • UTHR Buy
  • Analyst Count
  • KGC 4
  • UTHR 12
  • Target Price
  • KGC $14.50
  • UTHR $392.00
  • AVG Volume (30 Days)
  • KGC 21.8M
  • UTHR 477.3K
  • Earning Date
  • KGC 05-06-2025
  • UTHR 04-30-2025
  • Dividend Yield
  • KGC 0.81%
  • UTHR N/A
  • EPS Growth
  • KGC 177.99
  • UTHR 18.86
  • EPS
  • KGC 0.98
  • UTHR 25.10
  • Revenue
  • KGC $5,564,800,000.00
  • UTHR $2,994,100,000.00
  • Revenue This Year
  • KGC $18.69
  • UTHR $14.37
  • Revenue Next Year
  • KGC $2.19
  • UTHR $6.05
  • P/E Ratio
  • KGC $14.94
  • UTHR $12.70
  • Revenue Growth
  • KGC 26.71
  • UTHR 19.84
  • 52 Week Low
  • KGC $7.20
  • UTHR $266.98
  • 52 Week High
  • KGC $15.96
  • UTHR $417.82
  • Technical
  • Relative Strength Index (RSI)
  • KGC 65.12
  • UTHR 64.44
  • Support Level
  • KGC $14.49
  • UTHR $311.62
  • Resistance Level
  • KGC $14.92
  • UTHR $320.91
  • Average True Range (ATR)
  • KGC 0.34
  • UTHR 7.17
  • MACD
  • KGC 0.07
  • UTHR 1.63
  • Stochastic Oscillator
  • KGC 98.58
  • UTHR 89.55

About KGC Kinross Gold Corporation

Kinross Gold is a Canada-based gold producer, producing roughly 2.2 million gold equivalent ounces in 2023. The company had about a decade of gold reserves at the end of 2023. It operates mines in the Americas and West Africa after selling its low-cost Russian operations in 2022 in response to the invasion of Ukraine. The company has historically used acquisitions to fuel expansion into new regions and production growth. In 2022, Kinross purchased the Great Bear project in Canada, which, if developed, could produce an average of more than 500,000 ounces of gold per year for at least a decade.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: